FDA GLP-1 Compounding Enforcement: What Wholesale Distributors Need to Know About 2026 Compliance

FDA announced January 2025 that semaglutide and tirzepatide remain on the drug shortage list through Q2 2025, but signals accelerated enforcement against unlicensed compounders beginning in 2026. Wholesale distributors supplying active pharmaceutical ingredients (APIs) to compounding pharmacies face expanded liability for downstream use verification under 21 USC 353b and state pharmacy board enforcement actions targeting the supply chain.

Regulatory Context

The Federal Food, Drug, and Cosmetic Act Section 503B establishes requirements for outsourcing facilities that compound sterile drugs. Under 21 USC 353b(a)(1), these facilities must register with FDA, comply with current good manufacturing practice (cGMP) requirements under 21 CFR Parts 210 and 211, and report adverse events.

During a declared drug shortage, FDA exercises enforcement discretion under Section 503A, allowing state-licensed pharmacies to compound drugs appearing on FDA's shortage list without 503B registration. This discretion applies to semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) while the shortage persists.

State boards of pharmacy regulate traditional compounding pharmacies under Section 503A. These entities may compound patient-specific prescriptions but cannot engage in manufacturing-scale production. API sourcing requirements vary by state, but most require pharmacies to obtain bulk substances from FDA-registered facilities.

Key Details

FDA's January 2025 statement indicates semaglutide and tirzepatide will remain on the shortage list until approximately June 2025. Once removed, the agency will reinstate standard enforcement of 21 USC 353b against compounders operating without 503B registration.

The enforcement timeline creates a compliance cliff for the GLP-1 compounding market. Entities compounding these drugs without 503B status after shortage resolution face:

• Warning letters under 21 USC 331(a) for introducing unapproved drugs into interstate commerce
• Injunctions under 21 USC 332 to cease compounding operations
• Seizure actions under 21 USC 334 for adulterated or misbranded drugs
• State pharmacy board disciplinary action for exceeding traditional compounding scope

FDA has issued 14 warning letters to GLP-1 compounders since November 2023, primarily targeting entities making unsubstantiated drug claims or operating beyond 503A scope limits. The agency's 2026 enforcement priority shifts from marketing violations to manufacturing status verification.

Wholesale distributors supplying semaglutide or tirzepatide APIs must verify purchaser status before June 2025. Under 21 CFR 210.3(b)(16), only FDA-registered outsourcing facilities (503B) or licensed pharmacies operating within 503A limits may purchase bulk drug substances for compounding.

State boards of pharmacy in California, Texas, Florida, and Ohio have initiated enforcement actions against pharmacies receiving APIs from unlicensed sources. California Business and Professions Code Section 4127.1 requires pharmacies to obtain drugs only from licensed wholesalers. Texas Administrative Code 22 TAC 291.17 imposes similar sourcing restrictions.

Impact Assessment for Wholesale Distributors

Distributors holding wholesale drug licenses under state pharmacy statutes face direct compliance obligations:

API sourcing verification: Before distributing semaglutide or tirzepatide APIs after June 2025, distributors must confirm purchaser holds either active FDA 503B registration or state pharmacy license with traditional compounding authority. This requires checking FDA's Outsourcing Facility Database and state board licensure records.

Distribution records: Under 21 CFR 205.50(a), wholesale distributors must maintain pedigree records showing each prior sale, purchase, or trade of a prescription drug. API sales to unlicensed compounders create liability exposure if those entities face subsequent enforcement action.

State license conditions: Many state wholesale drug distributor licenses prohibit sales to unlicensed entities. Violations trigger administrative action by state boards of pharmacy, including license suspension under statutes like Ohio Revised Code 4729.57.

DSCSA implications: While APIs are currently excluded from Drug Supply Chain Security Act tracing requirements under 21 USC 360eee-1(3)(A), state-level pedigree requirements still apply. Distributors selling to entities later determined to be operating illegally may face challenges documenting legitimate supply chain participation during audits.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs, of which 1,234 hold active FDA registration. The remaining 41 entities operate under state wholesale licenses without FDA establishment registration — a status incompatible with API distribution to compounding pharmacies under 21 CFR 207.

The average compliance score across all tracked entities is 51/100, placing most distributors in the "Fair" tier. Only 28 entities (2.2%) achieve "Excellent" scores above 80, while 47 entities score below 40 ("Poor" or "Minimal" tiers). Distributors in lower tiers typically lack NABP accreditation or hold licenses in fewer than 10 states, signals of limited operational infrastructure for verifying downstream purchaser status.

Only 63 entities in the directory hold NABP Verified-Accredited Wholesale Distributors (VAWD) accreditation. NABP's accreditation criteria under VAWD Standard 3.2 require distributors to verify purchaser licensure before each transaction. This operational framework directly supports GLP-1 API sourcing compliance, but represents less than 5% of tracked entities.

73 entities have at least one FDA recall on record. While most recalls involve temperature excursions or labeling errors rather than unlicensed distribution, the presence of enforcement history indicates heightened FDA scrutiny during audits.

Practical Guidance for Compliance Teams

Verify API supplier status before June 2025: Use the ColdChainCheck directory to confirm your GLP-1 API supplier holds active FDA registration. Filter by "FDA Registration" data field. Entities without registration cannot legally distribute APIs to compounding pharmacies after the shortage ends.

Cross-reference NABP accreditation: Distributors with VAWD accreditation maintain documented purchaser verification processes. Search the directory for VAWD-accredited entities if your current supplier lacks this credential. The accreditation signals operational readiness for post-shortage compliance requirements.

Review downstream purchaser licenses: If you operate as a distributor, audit all entities purchasing semaglutide or tirzepatide APIs. Check FDA's Outsourcing Facility Database for 503B registrations. For 503A pharmacy purchasers, verify state pharmacy board licenses and confirm no prior enforcement actions for exceeding compounding scope.

Monitor state enforcement trends: ColdChainCheck tracks state-level compliance signals including license suspensions and board actions. California, Texas, Florida, and Ohio have initiated pharmacy board investigations targeting unlicensed compounding. Review entity records in these jurisdictions for recent disciplinary activity.

For comprehensive guidance on wholesale distributor compliance requirements, see ColdChainCheck's regulatory guides covering state licensure, FDA registration, and NABP accreditation standards.

Disclaimer: This article provides informational content based on publicly available regulatory data and is not legal or compliance advice. Consult your legal counsel and regulatory affairs team to assess your specific obligations under federal and state law.

Update: GLP-1 Compounding Compliance: FDA Enforcement for Distributors

March 22, 2026

GLP-1 Compounding Crackdown: What Wholesale Distributors Need to Know About FDA Enforcement and State Actions

On December 19, 2024, FDA removed tirzepatide (Mounjaro, Zepbound) from its drug shortage list, triggering immediate enforcement implications for compounding pharmacies manufacturing semaglutide and tirzepatide alternatives. Wholesale drug distributors sourcing or distributing compounded GLP-1 products through independent pharmacy channels face heightened scrutiny under FDA's compounding enforcement authority and parallel state board of pharmacy actions.

Regulatory Background: Compounding Under Drug Shortage Exception

Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), compounding pharmacies may compound copies of FDA-approved drugs only when the drug is in shortage, as listed on FDA's Drug Shortages Database. Section 503B outsourcing facilities—registered with FDA and subject to current good manufacturing practice (cGMP) requirements—face similar restrictions but operate under distinct registration and inspection requirements.

Semaglutide was placed on FDA's shortage list in March 2023 due to manufacturing capacity constraints by Novo Nordisk. Tirzepatide followed in December 2022 for the same reason. During the shortage period, compounding pharmacies legally produced alternative formulations, often marketed as "custom dosing" or "bioidentical" semaglutide. These products entered distribution channels through:

• Direct-to-patient mail-order from compounding pharmacies
• Wholesale distributors supplying independent retail pharmacies
• Specialty distributors serving telehealth platforms and weight-loss clinics

FDA's December 2024 decision to delist tirzepatide—following a reassessment of Eli Lilly's manufacturing output—immediately removes the statutory basis for compounding tirzepatide. Semaglutide remains on the shortage list as of January 2025, but FDA has indicated reassessment is ongoing.

FDA and State Enforcement Actions

FDA issued warning letters to 11 compounding entities in October 2024, citing violations including:

• Manufacturing tirzepatide products after delisting (21 U.S.C. § 353a)
• Marketing compounded products as "FDA-approved" or "bioidentical" when no such approval exists
• Distributing compounded products in bulk to wholesale distributors without patient-specific prescriptions, violating 503A's office-use exemption limits
• Operating as unregistered 503B outsourcing facilities while producing products for general distribution

State boards of pharmacy in Texas, California, and Florida issued parallel enforcement actions in November–December 2024, suspending licenses for compounding pharmacies found distributing GLP-1 products through wholesale channels without individualized prescriptions. Texas State Board of Pharmacy specifically cited violations of Texas Administrative Code § 291.133(c)(2), which prohibits pharmacies from distributing compounded preparations to entities other than practitioners or pharmacies for office use.

FDA's Bioresearch Monitoring (BIMO) division has increased unannounced inspections of 503B facilities producing semaglutide, with four facilities placed on import alert (Import Alert 66-41) in Q4 2024 for cGMP deficiencies.

Impact on Wholesale Drug Distributors

Wholesale drug distributors operating in GLP-1 compounding supply chains face three immediate compliance exposures:

1. Pedigree and traceability requirements under state law

Distributors must verify that compounded products received from 503A pharmacies or 503B facilities are accompanied by valid prescriptions or office-use documentation. Under California's Sherman Food, Drug, and Cosmetic Law (Health and Safety Code § 109985), distributors are prohibited from acquiring compounded drugs without documentation establishing lawful manufacture and intended use.

2. Liability under FD&C Act Section 301(k)

The FD&C Act prohibits the introduction into interstate commerce of any drug that is adulterated or misbranded. Compounded GLP-1 products manufactured after tirzepatide delisting are considered adulterated under Section 501 if they violate 503A or 503B requirements. Distributors who knowingly distribute adulterated products face enforcement action under Section 301(k), including warning letters, consent decrees, and potential criminal referral.

3. State wholesale drug distributor license conditions

Ohio Revised Code § 4729.60 and similar statutes in 22 states require wholesale drug distributors to maintain records demonstrating that all acquired products were legally manufactured. State boards of pharmacy conducting routine inspections of distributor facilities may review sourcing documentation for compounded products. Failure to demonstrate compliance with 503A/503B requirements may result in license suspension.

Distributors sourcing GLP-1 products must confirm whether the manufacturing pharmacy holds FDA registration as a 503B outsourcing facility (searchable via FDA's Outsourcing Facility Database) or operates under 503A exemptions. For 503A entities, distributors should obtain documentation proving patient-specific prescriptions exist for distributed units.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold active FDA registration—a baseline requirement for any distributor handling drug products, including those sourced from 503B outsourcing facilities. However, FDA registration alone does not indicate whether a distributor has appropriate controls for sourcing compounded products.

The average compliance score across all tracked entities is 51/100, placing the majority of distributors in the "Fair" tier (919 entities). Only 28 entities score in the "Excellent" range (76-100 points), reflecting full NABP accreditation, broad state licensure, and clean enforcement records. The compliance score does not yet incorporate 503B sourcing documentation or compounding pharmacy relationship disclosures—data points not systematically available in public databases.

Notably, 73 entities in the directory have at least one FDA recall on record. While most recalls relate to temperature excursions or labeling issues rather than compounding violations, entities with prior enforcement history may face heightened scrutiny during inspections if they distribute compounded GLP-1 products. State boards of pharmacy conducting post-shortage enforcement audits are likely to prioritize distributors with prior compliance gaps.

Practical Guidance for Compliance Officers

Verify 503B registration status for all compounding suppliers

Cross-reference any pharmacy claiming to supply compounded semaglutide against FDA's Outsourcing Facility Database (accessible at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities). If the pharmacy is not registered as a 503B facility, confirm it operates under 503A exemptions and request documentation proving patient-specific prescriptions for all distributed units.

Audit existing inventory sourced during the shortage period

Distributors holding tirzepatide inventory compounded before December 19, 2024, should segregate these products and consult legal counsel on disposition options. Distribution after delisting may constitute introduction of adulterated product into interstate commerce under 21 U.S.C. § 331(k).

Review trading partner agreements for compounding-specific representations

Contracts with compounding pharmacies should include representations that the pharmacy holds all required state licenses, complies with 503A or 503B requirements, and will notify the distributor immediately if removed from FDA's shortage list or if subjected to state board enforcement action.

Monitor state board enforcement databases

Texas, California, and Florida have published enforcement actions against compounding pharmacies in November–December 2024. Distributors sourcing from entities in these states should check state board of pharmacy public records for license suspensions or consent orders. ColdChainCheck tracks state license status for all entities in the directory and flags suspended or expired licenses in compliance scores.

Use the ColdChainCheck directory to verify FDA registration and state license status for any wholesale drug distributor or 3PL in your supply chain. For additional context on 503B facility compliance and NABP accreditation standards, see the compliance guides section.

Disclaimer: This article provides informational content based on publicly available regulatory guidance and enforcement actions as of January 2025. It is not legal or regulatory advice. Entities should consult legal counsel and review applicable statutes in their jurisdictions.